Cargando…

Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer

Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region. Hemolytic-uremic syndrome (HUS) associated with weekly gemcitabine for a breast cancer patient is...

Descripción completa

Detalles Bibliográficos
Autores principales: Kok, Victor C, Wu, Sheng-Chung, Lee, Chien-Kuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972075/
https://www.ncbi.nlm.nih.gov/pubmed/24701120
http://dx.doi.org/10.4137/BCBCR.S14920
_version_ 1782309541920112640
author Kok, Victor C
Wu, Sheng-Chung
Lee, Chien-Kuang
author_facet Kok, Victor C
Wu, Sheng-Chung
Lee, Chien-Kuang
author_sort Kok, Victor C
collection PubMed
description Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region. Hemolytic-uremic syndrome (HUS) associated with weekly gemcitabine for a breast cancer patient is extremely rare. We report here a case of 43-year-old woman with metastatic breast cancer who received weekly gemcitabine as a third-line palliative chemotherapy for her disease. She developed HUS after a cumulative dose of 11,000 mg/m(2) gemcitabine, evidenced by microangiopathic hemolytic anemia (MAHA) with schistocytes seen in peripheral blood smear, decreased haptoglobin level (<0.29 mmol/L), thrombocytopenia, negative direct Coombs test, and acute kidney injury. Owing to the ease of administration of weekly gemcitabine, gemcitabine-induced thrombocytopenia, multifactorial anemia in metastatic breast cancer, and possibility of cancer progression, HUS could have gone unnoticed. Breast cancer oncologist should be cognizant of this rare HUS even during weekly gemcitabine treatment.
format Online
Article
Text
id pubmed-3972075
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Libertas Academica
record_format MEDLINE/PubMed
spelling pubmed-39720752014-04-03 Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer Kok, Victor C Wu, Sheng-Chung Lee, Chien-Kuang Breast Cancer (Auckl) Case Report Sequential palliative chemotherapy for metastatic breast cancer incorporating weekly gemcitabine administered as three-weeks-on, one-week-off schedule is widely adopted throughout the East Asia region. Hemolytic-uremic syndrome (HUS) associated with weekly gemcitabine for a breast cancer patient is extremely rare. We report here a case of 43-year-old woman with metastatic breast cancer who received weekly gemcitabine as a third-line palliative chemotherapy for her disease. She developed HUS after a cumulative dose of 11,000 mg/m(2) gemcitabine, evidenced by microangiopathic hemolytic anemia (MAHA) with schistocytes seen in peripheral blood smear, decreased haptoglobin level (<0.29 mmol/L), thrombocytopenia, negative direct Coombs test, and acute kidney injury. Owing to the ease of administration of weekly gemcitabine, gemcitabine-induced thrombocytopenia, multifactorial anemia in metastatic breast cancer, and possibility of cancer progression, HUS could have gone unnoticed. Breast cancer oncologist should be cognizant of this rare HUS even during weekly gemcitabine treatment. Libertas Academica 2014-03-26 /pmc/articles/PMC3972075/ /pubmed/24701120 http://dx.doi.org/10.4137/BCBCR.S14920 Text en © 2014 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 License.
spellingShingle Case Report
Kok, Victor C
Wu, Sheng-Chung
Lee, Chien-Kuang
Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title_full Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title_fullStr Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title_full_unstemmed Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title_short Successful Remission of Hemolytic-Uremic Syndrome During the Third-line Weekly Gemcitabine for Metastatic Breast Cancer
title_sort successful remission of hemolytic-uremic syndrome during the third-line weekly gemcitabine for metastatic breast cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972075/
https://www.ncbi.nlm.nih.gov/pubmed/24701120
http://dx.doi.org/10.4137/BCBCR.S14920
work_keys_str_mv AT kokvictorc successfulremissionofhemolyticuremicsyndromeduringthethirdlineweeklygemcitabineformetastaticbreastcancer
AT wushengchung successfulremissionofhemolyticuremicsyndromeduringthethirdlineweeklygemcitabineformetastaticbreastcancer
AT leechienkuang successfulremissionofhemolyticuremicsyndromeduringthethirdlineweeklygemcitabineformetastaticbreastcancer